Skip to main content
. 2017 May 4;83(9):2096–2106. doi: 10.1111/bcp.13299

Figure 4.

Figure 4

Rates of new use of oral anticoagulants (OAC) with an indication for atrial fibrillation (A) and venous thromboembolism (B) in the UK Clinical Practice Research Datalink, from 2009 to 2015. NOAC, novel oral anticoagulants; VKA, vitamin K antagonists